Physician profile
Daniel E Van Buren
NPI 1942497615
$1,951.69
in general payments reported to CMS, 2019-2025
13 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $285 · 2021: $265 · 2022: $536 · 2023: $38.31 · 2024: $19.43 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $565.96 | 2019-2024 | Xarelto |
| Abbott Laboratories | $426.25 | 2019-2025 | Mitraclip |
| Pfizer INC. | $251.77 | 2019-2022 | |
| Amarin Pharma, INC. | $153.67 | 2020-2022 | |
| Edwards Lifesciences Corporation | $127.42 | 2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $126.30 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $100.03 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $91.30 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.91 | 2022 | |
| Allergan, INC. | $24.56 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.01 | 2019 | |
| Bridgebio Pharma, INC. | $17.92 | 2025 | Attruby |
| Baxter Healthcare | $15.59 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Van Buren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.